NCT05054725 2026-01-06Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesRevolution Medicines, Inc.Phase 2 Completed47 enrolled 17 charts
NCT04564027 2025-08-29A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced CancerAstraZenecaPhase 2 Completed54 enrolled 16 charts
NCT03309150 2024-11-29ATRi Transition Rollover StudyMerck KGaA, Darmstadt, GermanyPhase 1 Completed1 enrolled 4 charts
NCT04768296 2024-09-26Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)EMD SeronoPhase 2 Completed76 enrolled 42 charts
NCT02718300 2024-05-01A Study of INCB050465 in Combination With Ruxolitinib in Subjects With MyelofibrosisIncyte CorporationPhase 2 Terminated74 enrolled 40 charts
NCT01320085 2024-01-24A Phase II Study of Single Agent MEK162 in Patients With Advanced MelanomaPfizerPhase 2 Completed183 enrolled 35 charts
NCT03565991 2023-09-25Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid TumorsPfizerPhase 2 Terminated202 enrolled 31 charts